Celgene Awards Two Golden Tickets
to MBC BioLabs' Startups
Celgene has selected Nitrome Biosciences (left) and Synthex Labs (right) as recipients of their 2018 Golden Tickets. Nitrome Biosciences is developing drugs against a novel class of enzymes, initially targeting Parkinson's disease. SyntheX has a synthetic biology discovery platform for disrupting protein-protein interactions.
Please visit our new website
As we continue to grow and welcome new entrepreneurial scientists, we've updated our website to better reflect our community and mission. Take a peek.
To help our scientists be more efficient and to save time, we have implemented a lab supplies program called "AYCE" for All You Can Eat. We now have an unlimited supply of tips, tubes, gloves, and other basic items stocked on open shelves in the laboratory.
Celebration for ViewPoint Therapeutics
After closing a $35 million Series B, ViewPoint Therapeutics will be moving to their own lab space in South San Francisco. They were one of the very first companies to move into MBC BioLabs San Francisco, and they have grown from two to nine full time employees. Please join us as we congratulate their success and wish them well!
November 16, 2018 at 3:30 PM
953 Indiana Street, San Francisco
The MBC BioLabs San Carlos Open House on November 1 was a huge success with excellent scientific poster presentations from our resident companies and honored guests from our Founding Sponsor, NItto Denko.
GeneTether is an early stage biotechnology company developing improved gene editing technologies using Crispr/Cas, TALEN, and Zinc-Finger nucleases for human therapeutic applications. We are developing an approach that gives the DNA repair-templates the same "address" as the DNA strand breaks, ensuring their presence when needed for gene editing. This could improve gene editing efficiencies by over 100x while reducing unintended DNA damage and mutation.